Signup to have metrics tracked for this article

By signing up, social media discussions about Correction to: The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro‑entero‑pancreatic neuroendocrine tumours (GEP NETs) patients treated with [177Lu] Lu‑DOTATATE. will be collected and displayed on PubHawk. We'll also notify you by email on a monthly basis of any new updates captured on platforms like YouTube, Twitter/X, Bluesky, Facebook, LinkedIn, and more.
Your identifiable personal information will never be sold or shared to directly target you.

Please enter a valid email.
You must agree before submitting.

Example of Metrics tracking for this article:

Layout example
Correction to: The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro‑entero‑pancreatic neuroendocrine tumours (GEP NETs) patients treated with [177Lu] Lu‑DOTATATE.
Layout example